Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1230 entries
Sorted by: Best Match Show Resources per page
Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF

program design

[No authors listed]
GSID: VYoJUFPmwEIJ
GC Fonarow - Reviews in Cardiovascular Medicine, 2004 - europepmc.org

Patients with heart failure face a very high risk of hospitalizations and mortality. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors, beta-blockers …

Cite
Fonarow, G. C. (2004). Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF. Reviews in Cardiovascular Medicine, 5(S1), 45-54.
Fonarow, Gregg C. "Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF." Reviews in Cardiovascular Medicine 5.S1 (2004): 45-54.
Copy Download .nbib Format: MLA
Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review

program design

Abraham WT, Fonarow GC.
GSID: kVEHjFtsKeMJ
GC Fonarow, M Gheorghiade, WT Abraham - The American journal of …, 2004 - Elsevier

Patients who have had heart failure (HF) face very high risks of hospitalization and mortality. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors …

Cite
Fonarow, G. C., Gheorghiade, M., & Abraham, W. T. (2004). Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review. The American journal of cardiology, 94(9), 1155-1160.
Fonarow, Gregg C., Mihai Gheorghiade, and William T. Abraham. "Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review." The American journal of cardiology 94.9 (2004): 1155-1160.
Copy Download .nbib Format: MLA
Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.

International journal of endocrinology

Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K.
PMID: 23097668
Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11.

Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system. Hypertension can be generally treated by negating the effects of angiotensin II through the...

Cite
Ikeda K, Isaka T, Fujioka K, et al. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467doi: 10.1155/2012/519467.
Ikeda, K., Isaka, T., Fujioka, K., Manome, Y., & Tojo, K. (2012). Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. International journal of endocrinology, 2012519467. https://doi.org/10.1155/2012/519467
Ikeda, Keiichi, et al. "Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists." International journal of endocrinology vol. 2012 (2012): 519467. doi: https://doi.org/10.1155/2012/519467
Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11. PMID: 23097668; PMCID: PMC3477571.
Copy Download .nbib Format: NLM
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease.

Case reports in nephrology

Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M, Andrews J, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Zotta E.
PMID: 26942026
Case Rep Nephrol. 2016;2016:1492743. doi: 10.1155/2016/1492743. Epub 2016 Jan 28.

No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and...

Cite
Trimarchi H, Canzonieri R, Muryan A, et al. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol. 2016;2016:1492743doi: 10.1155/2016/1492743.
Trimarchi, H., Canzonieri, R., Muryan, A., Schiel, A., Araoz, A., Paulero, M., Andrews, J., Rengel, T., Forrester, M., Lombi, F., Pomeranz, V., Iriarte, R., & Zotta, E. (2016). Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case reports in nephrology, 20161492743. https://doi.org/10.1155/2016/1492743
Trimarchi, H, et al. "Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease." Case reports in nephrology vol. 2016 (2016): 1492743. doi: https://doi.org/10.1155/2016/1492743
Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M, Andrews J, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Zotta E. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol. 2016;2016:1492743. doi: 10.1155/2016/1492743. Epub 2016 Jan 28. PMID: 26942026; PMCID: PMC4749773.
Copy Download .nbib Format: NLM
Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication.

Kidney research and clinical practice

Kim JH, Lee SM, Son YK, Kim SE, An WS.
PMID: 28392998
Kidney Res Clin Pract. 2017 Mar;36(1):58-67. doi: 10.23876/j.krcp.2017.36.1.58. Epub 2017 Mar 31.

BACKGROUND: Previous studies have shown that a higher resistive index (RI) on renal duplex ultrasonography was related with renal progression and acute kidney injury, especially in patients with chronic kidney disease (CKD) using an angiotensin converting enzyme inhibitor (ACEI)...

Cite
Kim JH, Lee SM, Son YK, et al. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract. 2017;36(1):58-67doi: 10.23876/j.krcp.2017.36.1.58.
Kim, J. H., Lee, S. M., Son, Y. K., Kim, S. E., & An, W. S. (2017). Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney research and clinical practice, 36(1), 58-67. https://doi.org/10.23876/j.krcp.2017.36.1.58
Kim, Jae Hoon, et al. "Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication." Kidney research and clinical practice vol. 36,1 (2017): 58-67. doi: https://doi.org/10.23876/j.krcp.2017.36.1.58
Kim JH, Lee SM, Son YK, Kim SE, An WS. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract. 2017 Mar;36(1):58-67. doi: 10.23876/j.krcp.2017.36.1.58. Epub 2017 Mar 31. PMID: 28392998; PMCID: PMC5331976.
Copy Download .nbib Format: NLM
[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction].

Kardiologiia

Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS.
PMID: 28294911
Kardiologiia. 2015 Jul;55(7):14-25.

Simultaneous inhibition of the renin-angiotensin-aldosterone system and the system of degradation of natriuretic peptides can potentially provide unique therapeutic effects in patients with chronic heart failure (CHF) with reduced ejection fraction (EF). Aim of this study was to assess...

Cite
Kobalava ZD, Pavlikova EP, Averkov OA, et al. [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia. 2015;55(7):14-25
Kobalava, Z. D., Pavlikova, E. P., Averkov, O. A., Merai, I., Babaeva, L. A., Amirbegishvili, I. A., Kotovskaya, Y. V., & Moiseev, V. S. (2015). [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia, 55(7), 14-25.
Kobalava, Zh D, et al. "[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]." Kardiologiia vol. 55,7 (2015): 14-25.
Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS. [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia. 2015 Jul;55(7):14-25. Russian. PMID: 28294911.
Copy Download .nbib Format: NLM
Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Singh G, Manickam A, Sethuraman M, Rathod RC.
PMID: 26816449
Indian J Crit Care Med. 2015 Dec;19(12):731-4. doi: 10.4103/0972-5229.171410.

We describe a case of Takotsubo cardiomyopathy in a case of pituitary macroadenoma in acute adrenal crisis. A 48-year-old man presented with acute onset altered sensorium, vomiting, and gasping. On admission, he was unresponsive and hemodynamically unstable. He was...

Cite
Singh G, Manickam A, Sethuraman M, et al. Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian J Crit Care Med. 2015;19(12):731-4doi: 10.4103/0972-5229.171410.
Singh, G., Manickam, A., Sethuraman, M., & Rathod, R. C. (2015). Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 19(12), 731-4. https://doi.org/10.4103/0972-5229.171410
Singh, Georgene, et al. "Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 19,12 (2015): 731-4. doi: https://doi.org/10.4103/0972-5229.171410
Singh G, Manickam A, Sethuraman M, Rathod RC. Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian J Crit Care Med. 2015 Dec;19(12):731-4. doi: 10.4103/0972-5229.171410. PMID: 26816449; PMCID: PMC4711208.
Copy Download .nbib Format: NLM
Vascular endothelial dysfunction and pharmacological treatment.

World journal of cardiology

Su JB.
PMID: 26635921
World J Cardiol. 2015 Nov 26;7(11):719-41. doi: 10.4330/wjc.v7.i11.719.

The endothelium exerts multiple actions involving regulation of vascular permeability and tone, coagulation and fibrinolysis, inflammatory and immunological reactions and cell growth. Alterations of one or more such actions may cause vascular endothelial dysfunction. Different risk factors such as...

Cite
Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015;7(11):719-41doi: 10.4330/wjc.v7.i11.719.
Su, J. B. (2015). Vascular endothelial dysfunction and pharmacological treatment. World journal of cardiology, 7(11), 719-41. https://doi.org/10.4330/wjc.v7.i11.719
Su, Jin Bo. "Vascular endothelial dysfunction and pharmacological treatment." World journal of cardiology vol. 7,11 (2015): 719-41. doi: https://doi.org/10.4330/wjc.v7.i11.719
Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015 Nov 26;7(11):719-41. doi: 10.4330/wjc.v7.i11.719. PMID: 26635921; PMCID: PMC4660468.
Copy Download .nbib Format: NLM
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Therapeutics and clinical risk management

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q.
PMID: 25848291
Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015.

BACKGROUND: Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may...

Cite
Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449-67doi: 10.2147/TCRM.S80437.
Wang, Z. Y., Chen, M., Zhu, L. L., Yu, L. S., Zeng, S., Xiang, M. X., & Zhou, Q. (2015). Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and clinical risk management, 11449-67. https://doi.org/10.2147/TCRM.S80437
Wang, Zhi-Yu, et al. "Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy." Therapeutics and clinical risk management vol. 11 (2015): 449-67. doi: https://doi.org/10.2147/TCRM.S80437
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015. PMID: 25848291; PMCID: PMC4373598.
Copy Download .nbib Format: NLM
Guideline-directed medical therapy for secondary prevention after coronary artery bypass grafting in patients with depression.

International journal of cardiology. Heart & vessels

Stenman M, Holzmann MJ, Sartipy U.
PMID: 29450168
Int J Cardiol Heart Vessel. 2014 Mar 06;3:37-42. doi: 10.1016/j.ijchv.2014.02.005. eCollection 2014 Jun.

BACKGROUND: We hypothesized that depressed patients would have lower use of guideline-directed medical therapy for secondary prevention of cardiovascular events following coronary artery bypass grafting (CABG).METHODS: We included all patients who underwent primary isolated CABG in Sweden between 2006...

Cite
Stenman M, Holzmann MJ, Sartipy U. Guideline-directed medical therapy for secondary prevention after coronary artery bypass grafting in patients with depression. Int J Cardiol Heart Vessel. 2014;3:37-42doi: 10.1016/j.ijchv.2014.02.005.
Stenman, M., Holzmann, M. J., & Sartipy, U. (2014). Guideline-directed medical therapy for secondary prevention after coronary artery bypass grafting in patients with depression. International journal of cardiology. Heart & vessels, 337-42. https://doi.org/10.1016/j.ijchv.2014.02.005
Stenman, Malin, et al. "Guideline-directed medical therapy for secondary prevention after coronary artery bypass grafting in patients with depression." International journal of cardiology. Heart & vessels vol. 3 (2014): 37-42. doi: https://doi.org/10.1016/j.ijchv.2014.02.005
Stenman M, Holzmann MJ, Sartipy U. Guideline-directed medical therapy for secondary prevention after coronary artery bypass grafting in patients with depression. Int J Cardiol Heart Vessel. 2014 Mar 06;3:37-42. doi: 10.1016/j.ijchv.2014.02.005. eCollection 2014 Jun. PMID: 29450168; PMCID: PMC5801267.
Copy Download .nbib Format: NLM
Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan.

Acta Cardiologica Sinica

Lin CS, Chu YH, Hung YJ, Lee DY, Chen CY.
PMID: 27122755
Acta Cardiol Sin. 2013 Nov;29(6):539-49.

BACKGROUND: Hypertension control is of the utmost importance for reducing cardiovascular risk. In Taiwan, the hypertension control rate of the general population is low (25%). We investigated the factors affecting outpatient hypertension control to determine whether the low control...

Cite
Lin CS, Chu YH, Hung YJ, et al. Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan. Acta Cardiol Sin. 2013;29(6):539-49
Lin, C. S., Chu, Y. H., Hung, Y. J., Lee, D. Y., & Chen, C. Y. (2013). Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan. Acta Cardiologica Sinica, 29(6), 539-49.
Lin, Chung-Sheng, et al. "Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan." Acta Cardiologica Sinica vol. 29,6 (2013): 539-49.
Lin CS, Chu YH, Hung YJ, Lee DY, Chen CY. Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan. Acta Cardiol Sin. 2013 Nov;29(6):539-49. PMID: 27122755; PMCID: PMC4805033.
Copy Download .nbib Format: NLM
Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade.

World journal of hepatology

Souza-Mello V.
PMID: 28144388
World J Hepatol. 2017 Jan 18;9(2):74-79. doi: 10.4254/wjh.v9.i2.74.

Over the last decade, the role of renin-angiotensin system (RAS) on the development of obesity and its comorbidities has been extensively addressed. Both circulating and local RAS components are up-regulated in obesity and involved in non-alcoholic fatty liver disease...

Cite
Souza-Mello V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J Hepatol. 2017;9(2):74-79doi: 10.4254/wjh.v9.i2.74.
Souza-Mello, V. (2017). Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World journal of hepatology, 9(2), 74-79. https://doi.org/10.4254/wjh.v9.i2.74
Souza-Mello, Vanessa. "Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade." World journal of hepatology vol. 9,2 (2017): 74-79. doi: https://doi.org/10.4254/wjh.v9.i2.74
Souza-Mello V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J Hepatol. 2017 Jan 18;9(2):74-79. doi: 10.4254/wjh.v9.i2.74. PMID: 28144388; PMCID: PMC5241531.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1230 entries